Genitourinary Cancers

"We are confident that surgery for [testicular seminoma] will be included into treatment guidelines in the near future,” says Sia Daneshmand, MD.

In an episode of Cleveland Clinic’s Cancer Advances podcast, Christopher Weight, MD, center director of Urologic Oncology at Cleveland Clinic, discusses robot-assisted retroperitoneal lymph node dissection.

The program will feature leaders in GU robotic reconstruction and will emphasize novel techniques and innovation in managing complex reconstructive challenges.

The National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation

"People with kidney cancer have more effective treatment options than ever before. Not only are they living longer, they are living better,” said David Cella, PhD.

"Because testicular cancer is most often diagnosed in young men and treatments are very successful, the focus is on minimizing the short- and long-term impacts of treatment," says Sprenkle.

Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.

"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.

Although testicular cancer is rare, it is a disease that providers and patients should still be aware of, says Bradley C. Leibovich, MD, FACS.

Stigmas about the disease have negatively impacted the treatment and management of penile cancer, such that patients feel shamed for having the condition and do not seek care, and physicians may not have enough experience with the disease to appropriately provide care. Curtis A. Pettaway, MD, discusses these stigmas further in the following interview.

In a recent interview, Philippe E. Spiess, MD, and Andrea Necchi, MD, shared how they aim to develop an environment that emphasizes education, patient advocacy, and clinical research for rare genitourinary cancers.

Benefits include improved quality of life and symptom management.

In a recent study, investigators sought to understand the current viewpoints of the general population on testicular cancer and testicular self-examination.

“I think the big findings are that men know about testicular cancer, but they may not know a lot and they feel like they could know more,” says Shawn Dason, MD.

“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.

“The good news is that we’re getting really good at treating cancer and we have more survivors, but we need to start thinking more carefully about the non-cancer risks following a diagnosis, one of which is cardiovascular disease,” said senior author Ashley Felix, PhD.

"I hope many readers have taken the opportunity to learn from the evolving science and gone back to review the basics of virology, immune response, and clinical trial development to gain a better understanding of this global pathogen," writes Raoul S. Concepcion, MD, FACS.

A nurse practitioner discusses how she supports multiple providers in a large academic practice.

The rates of mental healthcare use were significantly higher for patients versus healthy controls during diagnosis, treatment, and long-term survivorship.

Adam J. Gadzinski, MD, MS, highlights positive outcomes of telemedicine multidisciplinary urologic cancer clinics implemented by the University of Washington/Seattle Cancer Care Alliance.

The data demonstrate how the implementation of a telehealth pathway helped reverse the initial urologic-oncologic outpatient volume decline at an institution during the pandemic.

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.

Among patients with adrenocortical cancer, 60% to 70% relapse after surgery, making novel therapeutics an area of high unmet medical need.

The study also found that among patients with a primary testicular germ cell tumor (TGCT), the incidence of contralateral TGCT increased up to 20 years after initial diagnosis.

The risk was decreased further with each additional chemotherapy cycle a patient received.

"The 21st century has ushered in technology that has created more access and readily available information at our fingertips," Raoul S. Concepcion, MD, FACS.

Urologists and patients show resilience, but we must be better prepared in the future, says urologist R. Jonathan Henderson, MD.

Patients with cancer are particularly susceptible to negative consequences of COVID-19.

A 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.

A standardized, multidisciplinary approach led to similar outcomes based on disease characteristics, not sociodemographic factors.